Search results
Results from the WOW.Com Content Network
Sofosbuvir/velpatasvir was developed by the pharmaceutical company Gilead Sciences and approved by the U.S. Food and Drug Administration (FDA) in June 2016. [13] In the European Union it was approved in July 2016, for the treatment of chronic hepatitis C virus infection in adults.
Research involving more than 1,900 college-age men found that four percent of otherwise healthy undergraduates reported recreationally using ED drugs like Viagra. More than 70 percent of these ...
The U.S. Food and Drug Administration is asking a panel of experts to weigh in on a women's version of the male sexual dysfunction drug Viagra. The FDA is considering Boehringer Ingelheim's drug ...
The U.S. Food and Drug Administration (FDA) has approved several medications for the treatment of ED, including: Sildenafil (the active ingredient in Viagra or generic versions of Viagra ...
Following its approval by the FDA in 2013, [34] the price of sofosbuvir as quoted in various media sources in 2014 ranged from $84,000 to $168,000 depending on course of treatment in the U.S. [39] and £35,000 in the United Kingdom for a 12-week regimine, [40] causing considerable controversy.
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). [4] [5] The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. [6]
Therefore, there’s no true equivalent of a Viagra-like medication for women on the market, simply because genital function is different between the sexes. Yet women do experience sexual ...
A panel of U.S. Food and Drug Administration experts decided Friday that Boehringer Ingelheim's so-called "female viagra" drug, flibanserin, doesn't provide enough benefit to outweigh the risks.